BFS
VIR icon

Bare Financial Services’s Vir Biotechnology VIR Stock Holding History

Bare Financial Services’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$988 Hold
97
– – ﹤0.01% 1391
2026
Q1 		$869 Hold
97
– – ﹤0.01% 1313
2025
Q4 		$585 Hold
97
– – ﹤0.01% 1315
2025
Q3 		$554 Buy
+97
New +$496 ﹤0.01% 1232

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bare Financial Services's VIR Position: Q2 2026 in Review

Bare Financial Services held its Vir Biotechnology (VIR) position steady in Q2 2026 at 97 shares worth $988. The position accounts for ﹤0.01% of the portfolio, ranked #1391.

Bare Financial Services first reported a position in VIR in Q3 2025 and has held it in 4 quarters since. 238 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Bare Financial Services held 97 shares of Vir Biotechnology worth $988 as of Q2 2026.
  • Bare Financial Services left its Vir Biotechnology share count unchanged in Q2 2026.
  • Vir Biotechnology made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1391 holding.
  • Bare Financial Services first reported a position in Vir Biotechnology in Q3 2025 and has held it in 4 quarters since.
  • 238 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.